Dermatology
Case Report
A Case of Nonscarring Subepidermal Blistering Disease Associated with Autoantibodies Reactive with Both Type VII Collagen and Laminin 5Umemoto N.a · Demitsu T.a · Toda S.a · Ohsawa M.a · Noguchi T.b · Kakurai M.c · Yamada T.c · Suzuki M.c · Nakagawa H.c · Komai A.d · Hashimoto T.dDepartments of aDermatology and bDentistry and Oral Surgery, Jichi Medical School – Omiya Medical Center, Omiya, cDepartment of Dermatology, Jichi Medical School – School of Medicine, Tochigi, and dDepartment of Dermatology, Kurume University School of Medicine, Kurume, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: August 26, 2002
Accepted: November 22, 2002
Published online: July 18, 2003
Issue release date: 2003
Number of Print Pages: 4
Number of Figures: 5
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Abstract
A 35-year-old Japanese woman had recurrent, pruritic, vesicular lesions on the face, neck and upper back as well as erosive lesions of the oral cavity and genitalia. The skin and mucosal lesions healed without scarring upon the systemic administration of corticosteroid and azathioprine. Direct immunofluorescence revealed linear deposits of IgG, IgA and C3 at the cutaneous basement membrane zone. Indirect immunofluorescence on 1 M NaCl-split human skin sections demonstrated that the patient’s IgG antibodies reacted with the dermal side of the split, while IgA antibodies weakly reacted with the epidermal side. By immunoblot analyses, the patient’s serum reacted with the NC1 domain of type VII collagen as well as both the α3- and β3-subunits of laminin 5. We regarded our case as a nonscarring subepidermal blistering disease with autoantibodies to both type VII collagen and two different subunits of laminin 5. Such a case has not been previously reported.
© 2003 S. Karger AG, Basel
Related Articles:
References
- Schmidt E, Zillikens D: Autoimmune and inherited subepidermal blistering diseases: Advances in the clinic and the laboratory. Adv Dermatol 2000;16:113–157.
-
Kawahara Y, Zillikens D, Yancey KB, Marinkovich MP, Nie Z, Hashimoto T, et al: Subepidermal blistering disease with autoantibodies against a novel dermal 200-kD antigen. J Dermatol Sci 2000;23:93–102.
External Resources
- Tanaka H, ishida-Yamamoto A, Hashimoto T, Hiramoto K, Harada T, Kawachi Y, et al: A novel variant of acquired epidermolysis bullosa with autoantibodies against the central triple-helical domain of type VII collagen. Lab Invest 1997;77:623–632.
- Nie Z, Nagata Y, Joubeh S, Hirako Y, Owaribe K, Kitajima Y, et al: IgA antibodies of linear IgA bullous dermatosis recognize the 15th collagenous domain of BP180. J Invest Dermatol 2000;115:1164–1166.
- Choi GS, Lee ES, Kim SC, Lee S: Epidermolysis bullosa acquisita localized to the face. J Dermatol 1998;25:19–22.
- Zillikens D, Ishiko A, Jonkman MF, Chimanovich I, Simizu H, Hashimoto T, et al: Autoantibodies in anti-p200 pemphigoid stain skin lacking laminin 5 and type VII collagen. Br J Dermatol 2000;143:1043–1049.
- Chan LS, Lapière JC, Chen M, Traczyk T, Mancini AJ, Paller AS, et al: Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol 1999;135:569–573.
- Jonkman MF, Schuur J, Dijk F, Heeres K, de Jong MC, van der Meer JB, et al: Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin alpha3. Arch Dermatol 2000;136:227–231.
Article / Publication Details
Received: August 26, 2002
Accepted: November 22, 2002
Published online: July 18, 2003
Issue release date: 2003
Number of Print Pages: 4
Number of Figures: 5
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
